Highest-materiality recent filing
Syndax Q2 2026 revenue $72.8M; Revuforj net revenue $54.7M (+91% YoY); Niktimvo $60.3M (+67%)
Total revenue $72.8M (Revuforj $54.7M, Niktimvo collaboration $18.1M); H1 2026 net loss $49.4M vs $71.8M prior year.
Syndax unveils SNDX-4321 (allosteric EGFRi) and SNDX-62122 (menin inhibitor) at R&D event
SNDX-4321: novel mutant-selective allosteric EGFR inhibitor for NSCLC; IND expected by end of 2026, Phase 1 in 2027.
Syndax issues $250M of 2.25% convertible notes due 2031, net proceeds ~$243M
Issued $250M aggregate principal amount of 2.25% Convertible Senior Notes due 2031 in private placement.
Syndax shareholders approve 2026 equity plans; 7.2M new shares reserved
Stockholders approved 2026 Equity Incentive Plan authorizing 7,200,000 new shares plus returning shares from prior plan.
Syndax raises $250M via 2.25% convertible notes due 2031; conversion price at 35% premium
$250M aggregate principal, 2.25% interest, semiannual payments starting Dec 15, 2026, maturing June 15, 2031.
Syndax Q1 revenue up 224% to $64.9M; net loss narrows to $42.7M from $84.8M
Revuforj net revenue $48.9M (+144% YoY, +11% QoQ); total prescriptions up ~160% YoY.
Syndax Q4 Revuforj $44.2M (+38% QoQ); Niktimvo $56M; net loss $68M
Total revenue $68.7M in Q4 and $172.4M in FY2025, driven by Revuforj and Niktimvo launches.
Syndax reports preliminary 2025 Revuforj $125M, Niktimvo $152M net rev, cash $394M
Revuforj preliminary net revenue $44M (Q4) and $125M (FY), up 38% QoQ.
Syndax amends Bylaws to move to uncertificated shares effective Dec 18, 2025
Board approved Bylaw amendment on Dec 18, 2025 requiring all future share issuances to be uncertificated.
Syndax reports Q3 2025 revenue $45.9M, Revuforj net sales $32M; FDA approval for NPM1m AML on Oct 24
Total revenue $45.9M (Revuforj net $32.0M, +12% vs Q2; Niktimvo collab $13.9M).
Syndax receives FDA approval for Revuforj in NPM1-mutated R/R AML, second indication in <1 year
FDA approved Revuforj (revumenib) for R/R AML with NPM1 mutation in patients aged ≥1 year.
Syndax Q2 Revuforj revenue $28.6M (+43% QoQ); sNDA for mNPM1 AML with Priority Review
Revuforj net revenue $28.6M in Q2 2025, 43% increase over Q1 2025.
Director William Meury resigns from Syndax board to become Incyte CEO
William Meury resigned from Syndax board effective June 24, 2025.
Syndax names Dr. Nicholas Botwood Head of R&D and CMO, replacing Neil Gallagher
Dr. Nicholas Botwood appointed Head of R&D and CMO, effective May 12, 2025; succeeds Dr. Neil Gallagher who is departing.
Syndax Q1 Revuforj rev $20M, Niktimvo rev $13.6M; sNDA for mNPM1 AML
Revuforj net revenue $20.0M in first full quarter; Niktimvo net revenue $13.6M (Incyte reported) in first partial quarter.
Syndax Q4 Revuforj revenue $7.7M; net loss $94.2M; cash $692.4M
Q4 2024 Revuforj net product revenue $7.7M in first five weeks of U.S. launch.
Syndax eliminates Chief Medical Officer role; Dr. Catherine Madigan departs
CMO Catherine Madigan, M.D. ceased employment effective December 20, 2024, after position eliminated.
FDA approved Revuforj for R/R acute leukemia with KMT2A translocation in patients aged 1+ years.
Syndax reports positive pivotal Phase 2 results for revumenib in R/R mNPM1 AML; CR/CRh 23%
Primary endpoint met: CR/CRh rate 23% (15/64; 95% CI 14%–36%; p=0.0014) in efficacy-evaluable adult patients.
Syndax Q3 net loss $84.1M; revumenib PDUFA Dec 26; Niktimvo approved; $350M royalty funding
Net loss $84.1M ($0.98/share) vs $51.1M ($0.73) in Q3 2023; R&D $71.0M, SG&A $31.1M.
Syndax sells 13.8% royalty on Niktimvo (axatilimab) to Royalty Pharma for $350M upfront
Royalty Pharma acquires right to 13.8% of net sales of Niktimvo (axatilimab) in US and territories.
Syndax Q2 net loss $68.1M, revumenib PDUFA extended to Dec 26, 2024
Net loss of $68.1M ($0.80/sh) vs $44.6M ($0.64/sh) in Q2 2023; cash $454.6M as of June 30.
Syndax appoints Aleksandra Rizo to Board; Morrison resigns; annual meeting votes passed
Aleksandra Rizo, M.D., Ph.D., elected to Board effective May 15, replacing Briggs Morrison who resigned.
Syndax Q1 net loss $72.4M ($0.85/shr); revumenib NDA & axatilimab BLA under Priority Review
Cash, equivalents and investments $522M; management believes sufficient for operations through 2026.
Syndax appoints Steven Closter as CCO as Steve Sabus resigns; expects two product launches in 2024
Steve Sabus voluntarily resigned as CCO on March 15, 2024 due to personal reasons.
Syndax reports FY2023 net loss $209.4M; axatilimab PDUFA Aug 28, 2024; cash $600M through 2026
Net loss for FY2023: $209.4M ($2.98 per share) vs $149.3M ($2.46 per share) in 2022.
Syndax closes $230M public offering of common stock at $18.50/share
Offering of 12,432,431 shares includes full exercise of underwriters' option to purchase 1,621,621 additional shares.
Syndax announces $200M public offering of common stock at $18.50/share
Issued 10,810,810 shares at $18.50; gross proceeds ~$200M ($230M with overallotment).
Axatilimab AGAVE-201 trial met primary endpoint: 74% ORR at 0.3 mg/kg every two weeks in refractory chronic GVHD; BLA submission planned by year-end 2023.
Syndax reports Q3 net loss $0.73/sh, initiates revumenib NDA in R/R KMT2Ar leukemia
Net loss $51.1M ($0.73/sh) vs $35.4M ($0.58/sh) YoY; cash $379.3M as of Sep 30, 2023.
Syndax revumenib meets primary endpoint in pivotal AUGMENT-101 trial; CR/CRh 23% (p=0.0036)
Primary endpoint met with CR/CRh 23% (13/57) in pooled KMT2Ar acute leukemia; p=0.0036.
Syndax Q2 net loss $44.6M; axatilimab ORR up to 74% in cGVHD; two filings on track for 2023
Axatilimab AGAVE-201: ORR 74% at 0.3 mg/kg Q2W; all three cohorts met primary endpoint in cGVHD.
Syndax/Incyte axatilimab hits primary endpoint in cGVHD trial; 74% ORR at 0.3 mg/kg dose
AGAVE-201 met primary endpoint: ORR 74% (0.3 mg/kg Q2W), 67% (1.0 mg/kg), 50% (3.0 mg/kg Q4W).
Syndax enters new $200M at-the-market equity facility with TD Cowen, replacing prior $75M program
Prior $75M ATM facility terminated on March 26, 2023; gross proceeds of $25M raised before termination.
Syndax shareholders approve increase in authorized shares from 110M to 210M
Amendment to certificate of incorporation increases authorized shares: 200M common stock + 10M preferred stock.
Syndax Q1 net loss $41.1M; on track for two pivotal readouts and NDA/BLA filings in 2023
Net loss of $41.1M ($0.59/sh) vs $37.2M ($0.63/sh) YoY; cash $449M as of Mar 31, 2023.
Syndax appoints Neil Gallagher as President, Head of R&D; Morrison transitions
Neil Gallagher, M.D., Ph.D., appointed President, Head of R&D effective April 10, 2023; previously CMO at AbbVie.
Syndax Q4 2022 net loss $39.2M; revumenib topline data expected Q3 2023
Net loss of $39.2M ($0.62 per share) for Q4 2022 vs net gain of $96.2M ($1.81) in Q4 2021.
Syndax adopts 2023 Inducement Plan, reserving 1.9M shares for new-hire equity grants
Board approved 2023 Inducement Plan on Feb 2, 2023, under Nasdaq Rule 5635(c)(4) for inducement grants.
Syndax closes $172.5M public offering; shares outstanding ~68.1M
Gross proceeds of $172.5M from 7,840,909 shares at $22.00 per share.
Syndax Pharmaceuticals prices $150M public offering of 6.8M shares at $22.00 per share
6,818,182 shares offered at $22.00 each; underwriters have 30-day option for 1,022,727 additional shares.
Syndax appoints Steve Sabus as CCO; base $495K, option for 220K shares
Steve Sabus joins as Chief Commercial Officer effective December 5, 2022.
Syndax Q3 net loss $35.4M; revumenib Phase 1 shows 30% CR/CRh rate, 9.1 mo median durability
Net loss $35.4M ($0.58 per share) vs $20.6M ($0.40) prior year; cash $337.8M at Sep 30.
Syndax prepays $21.5M loan, terminates Hercules Capital credit agreement
Prepaid $21.5M to Hercules Capital to satisfy all principal, interest, and fees under Feb 2020 loan; includes $1.0M end-of-term fee and $0.4M prepayment fee.
Syndax Q2 net loss $37.6M ($0.62/sh); on track for pivotal data in 1H23
Cash $378.9M; net loss $37.6M ($0.62/sh) vs $22.9M ($0.44/sh) year ago.
Syndax appoints Keith A. Goldan as CFO; base salary $450k, option for 230k shares
Keith Goldan appointed CFO effective June 13, 2022; previously CFO at OptiNose.
Syndax stockholders elect directors, approve say-on-pay, ratify auditor at 2022 annual meeting
All three director nominees elected: Katkin 27.7M for/16.4M withheld, Morrison 25.4M/18.7M, Podlesak 23.4M/20.7M.
Syndax Q1 2022 net loss $37.2M; cash $397.9M; clinical milestones on track for 2023
Net loss $37.2M ($0.63/sh) vs $27.7M ($0.54) in Q1 2021; R&D spend $30.0M vs $21.9M.
Syndax reports Q4 net profit of $96.2M from Incyte deal; names new CMO
Net profit $96.2M ($1.81/sh) vs loss $20.4M prior Q; revenue $126.6M from Incyte collaboration.
Director Fabrice Egros resigns from Syndax board; Dennis Podlesak joins Audit Committee
Fabrice Egros resigned from Syndax board effective Feb 23, 2022 due to expanded role at Lupin Limited.
Nicholas A.J. Botwood, BSC (HONS), MB BS, MFPM, FRCP, will join the Company as Head of Research and Development, Chief Medical Officer, effective May 12, 2025.
Neil Gallagher, M.D. Ph.D, President, Head of Research and Development of the Company, notified the Company of his intention to resign from his position as President, Head of Research and Development.
On May 15, 2024, the Board of Directors (the “ Board ”) of Syndax Pharmaceuticals, Inc. (the “ Company ”), unanimously voted to elect Aleksandra Rizo, M.D., Ph.D. to the Board, effectively immediately
On May 14, 2024, Briggs W. Morrison, M.D. advised the Board that he will resign from his position as a Class III member of our Board effective immediately.
On March 18, 2024, Syndax Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing that Steven Closter will join the Company as Chief Commercial Officer, effective immediately.
On March 15, 2024, Steve Sabus, the previous Chief Commercial Officer of the Company, notified the Company of his voluntary resignation from his position due to personal reasons.
Effective May 5, 2023, Alexander Nolte resigned from his positions as the Company’s Vice President, Chief Accounting Officer and its Principal Accounting Officer, in order to pursue another opportunity.
The Company has appointed Keith A. Goldan, the Company’s Chief Financial Officer, Treasurer and its Principal Financial Officer, as its Principal Accounting Officer.
On March 29, 2023, Briggs W. Morrison M.D., President, Head of Research and Development of the Company, notified the Company of his intention to resign from his position as President, Head of Research and Development.
On March 30, 2023, Syndax Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing that Neil Gallagher, M.D., Ph.D., will join the Company as President, Head of Research and Development, effective April 10, 2023.
On December 2, 2022, Syndax Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing that Steve Sabus will join the Company as Chief Commercial Officer, effective December 5, 2022.
On June 13, 2022, Syndax Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing that Keith A. Goldan will join the Company as Chief Financial Officer, effective June 13, 2022.
Max materiality 0.95 · Median 0.70 · Most common event earnings